Ambrosia Biosciences Secures $100 Million in Oversubscribed Series B Round to Fuel Cardiometabolic Research

Ambrosia Biosciences Secures $100 Million in Oversubscribed Series B Financing

Ambrosia Biosciences Inc., a pioneering drug discovery company, has recently announced the closing of a $100 million oversubscribed Series B financing round. This significant funding is earmarked for the development of its novel oral small molecule GLP-1 candidate that targets cardiometabolic conditions, along with various other innovative therapeutic programs.

The financing was co-led by prominent new investors such as Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital. The existing investors BVF Partners and Boulder Ventures also participated, alongside new entrants like Janus Henderson Investors and Samsara BioCapital, demonstrating extensive support from both new and existing stakeholders.

The capital obtained through this financing is primarily intended to propel the Company towards the initiation of clinical trials for its oral small molecule GLP-1 program. Among the additional projects supported by this funding is the continued development of various small molecule programs focusing on GIP and amylin, essential in addressing obesity and other metabolic disorders.

Founder and CEO Nick Traggis shared his enthusiasm regarding this financing, stating, "This financing represents a strong endorsement of our team, science, and pipeline. It shows investor conviction in next-generation oral cardiometabolic therapies." He highlighted the potential of Ambrosia's approaches as they move beyond first-generation therapies and capitalize on the opportunity to create differentiated small molecule proton modulators formulated for combinatory treatments.

The focus of Ambrosia is on creating a portfolio of small molecules that are orally bioavailable and aim at key metabolic G-protein coupled receptors (GPCRs), such as GLP-1, GIP, and amylin. The Company's unique strategy combines advancements in structural biology with cutting-edge computational chemistry, resulting in the development of molecules that possess differentiated pharmacological profiles. These innovations not only enhance standalone therapy effectiveness but also cater to strategic combinations for managing obesity and the accompanying cardiometabolic diseases.

Sara Clarke, Ph.D., Vice President of Blue Owl Capital, expressed her optimism about Ambrosia's potential. She stated, "With first-generation oral GLP-1 therapies now approved, we believe Ambrosia is well positioned to develop differentiated small molecule therapies with best-in-class potential." Clarke's involvement extends beyond investment, as she will also join Ambrosia’s Board of Directors, further solidifying the relationship between Ambrosia and its supporters.

Ambrosia Biosciences is committed to advancing its clinical programs and expanding its pipeline of innovative treatments that target significant health challenges associated with weight management and metabolic disorders. The funding marks a compelling milestone for the Company, reinforcing its vision of addressing the unmet medical needs within the cardiometabolic arena.

As Ambrosia moves forward, it aims to leverage this financing to advance not only its lead GLP-1 program but also to broaden its small molecule pipeline, positioning itself as a leader in the emerging landscape of cardiometabolic therapies.

For further details about Ambrosia Biosciences and its innovative research, please visit Ambrosia Biosciences Inc..